In Brief: Neoprobe
This article was originally published in The Gray Sheet
Executive Summary
Neoprobe: Firm launches Neoprobe 1500 portable radioisotope detector Oct. 13 at American College of Surgeons conference in Chicago. The hand-held gamma ray detector intraoperatively tracks radiopharmaceuticals used in the body in lymphatic mapping for melanoma patients and location of breast cancer. The Neoprobe 1500 consists of a microprocessor-based unit that transmits probe-detected gamma pulses into displays and sounds, and features sound-guided detection. Three reusable probe tips are offered for use with one single-use handle; all probes employ cadmium zinc telluride crystals to detect isotopes such as Indium-111, Iodine-125 and Technetium-99m...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.